September 10, 2017 – Results from the BMS-sponsored CheckMate-214 phase-3 trial, for which Dr. Hammers is a co-PI, are presented at the European Society for Medical Oncology annual meeting, and show improved overall survival with ipilimumab/nivolumab compared to sunitinib heralding a new standard of care for patients with metastatic kidney cancer. Press Release • Interview
September 8, 2017 – The Urology Department, the surgical backbone of the Kidney Cancer Program, will be spearheading urologic care at John Peter Smith Hospital (also known as JPS Hospital), a 573-bed county hospital in Fort Worth, ensuring that Tarrant County residents get state-of-the-art urologic care, including robotic partial nephrectomy, laparoscopic and robotic radical nephrectomy, and advanced cancer care in a multi-disciplinary format. Tarrant county residents will benefit from the Kidney Cancer Program thought leaders in urology, medical oncology, radiation oncology, pathology, and radiology, who will review complex cases in a virtual multi-disciplinary format to ensure that the highest caliber care is delivered. We are very excited and proud to offer our services to this unique group of patients.
September 5, 2017 – The KCP launches a private patient support Facebook page, a dedicated forum for kidney cancer patients and their family and friends to discuss issues, questions, and concerns, and to help support each other on their journeys.
August 21, 2017 – Dr. Ananth Madhuranthakam, Assistant Professor in the Dept. of Radiology and the Advanced Imaging Research Center, is awarded an NIH U01 grant. This 5-year grant focuses on establishing arterial spin labeling (ASL) as a quantitative imaging biomarker to monitor treatment response in glioblastoma and metastatic RCC. With this grant, his group becomes a member of the Quantitative Imaging Network (QIN) assembled by the NCI to establish quantitative imaging methods and software tools for cancer therapy response. About 15 sites are currently part of this network, but this is the first to focus on ASL in any cancer, and the first project to focus on RCC.
August 9, 2017 – KCP researchers report in Cancer Discovery the development of mouse models of the two most common types of kidney cancer, and show that the BAP1 and PBRM1 genes control kidney cancer aggressiveness. Press Release • Video
August 1, 2017 – Six outstanding awardees will be supported as part of SPORE Year 2 Developmental Research and Career Enhancement Programs (DRP and CEP). The DRP awardees are: Drs. Jeff Cadeddu, Chuo Chen, JT Hsieh, and Yihong Wan. CEP awards went to Drs. Laura Banaszynski and Guiyang Hao. Research proposal topics ranged from epigenetic dysregulation of metabolism in RCC to novel immunotherapy reagents. (More details on the KCP FB page, where each awardee will be featured sequentially.)
July 6, 2017 – Dr. Hammers is lead author on a study published in the Journal of Clinical Oncology demonstrating a doubling of response rate, from 20 percent to 40 percent, in kidney cancer patients undergoing combination immunotherapy with ipilimumab plus nivolumab. Press Release
April 12, 2017 – Dr. Hannan and colleagues report UTSW experience with stereotactic radiation for metastatic renal cancer. The article, which shows 1-year local control rates greater than 90 percent, represents one of the largest experiences reported in the literature to date. Press Release
March 25, 2017 – Joey's Wings 5K Walk/Run is held at Arbor Hills Park in Plano, Texas with proceeds going to support KCP kidney cancer research.
February 25, 2017 – The Rock the Cure for Kidney Cancer fundraising event, organized by KCP patient advocates, is held at the Dallas Country Club. The event raises over $100,000 for the KCP for kidney cancer research. Pictures
February 6, 2017 – KCP investigators report that a primary lung cancer may be identified in more than 5 percent of patients with metastatic RCC, where it may be undiagnosed, and identify radiographic and clinical features that aid in distinguishing between a new primary lung cancer versus progression of metastatic disease. Article • Press Release
December 22, 2016 – Dr. Kapur is appointed to the NCI Renal Cancer Task Force, which supports NCI’s Genitourinary Cancers Steering Committee. The task force is charged with promoting the best clinical and translational research by critically reviewing phase 2 and phase 3 clinical trial concepts. She becomes the 5th UT Southwestern faculty member appointed to the task force, along with Drs. Pedrosa, Brugarolas, Hammers, and Hannan.
December 1, 2016 – The KCP holds its External Advisory Board meeting, an important forum for updating and getting feedback from our distinguished EAB members.
November 18, 2016 - UTSW performs first case of intraoperative radiation therapy for a patient with metastatic kidney cancer and a challenging resection.
October 1, 2016 – Five outstanding awardees were awarded one-year research grants as part of the SPORE Year 1 Developmental Research and Career Enhancement Programs (DRP and CEP). The DRP awardees are: Drs. Thomas Carroll, Benjamin Chen, and Yihong Wan. CEP awards went to Drs. Ralph Mason and Xuewu Zhang. Research proposal topics ranged from radioresistance in RCC to mechanisms underlying bone metastasis.
September 23, 2016 – KCCure interviews Dr. Brugarolas about the HIF-2 inhibitor in clinical trials. Interview
September 5, 2016 – UT Southwestern researchers and colleagues report their study in the journal Nature on the efficacy of a new class of RCC treatment, a HIF-2 inhibitor (PT2399), in their preclinical RCC tumorgraft model. Press Release
August 29, 2016 – Dr. Brugarolas is invited to become a member of the Renal Task Force of the Genitourinary Cancer Steering Committee of the National Cancer Institute and nominates Dr. Hammers, who is also appointed to the Task Force.
August 1, 2016 – The KCP is awarded an $11 million Specialized Program of Research Excellence (SPORE) grant for translational kidney cancer research. This is only the second SPORE grant awarded for kidney cancer in the history of NCI’s Translational Research Program, and the first awarded to a single institution.
June 15, 2016 – The KCP works with the Office of Quality Improvement to develop protocols for measuring outcomes across cancer types.
June 10, 2016 – The KCP works with the Office of Information Systems to develop protocols to automatically extract information from the electronic medical record that can be linked to research samples and genomics.
June 3, 2016 – Dr. Kevin Courtney presents results from the Phase I trial of a first-in-class oral HIF-2a inhibitor at the 2016 ASCO meeting in Chicago; the trial showed that the inhibitor is safe and had activity in heavily pretreated patients with advanced ccRCC.
June 1, 2016 – Dr. Hans Hammers, who led the kidney cancer oncology program at Johns Hopkins, joins the UTSW Kidney Cancer Program as a Co-Leader for clinical research. Dr. Hammers is the recipient of the inaugural Eugene P. Frenkel Endowed Scholar Award. His research program focuses on immunotherapy for kidney cancer. We are thrilled to have him join the KCP.
May 19, 2016 – The KCP hosts Dr. Fraydoon Rastinejad, Professor at Sanford-Burnham-Prebys, who discusses novel vulnerabilities in HIF transcription factors, which are key drivers of renal cancer development.
April 2016 – Dr. Hannan, along with Drs. Pedrosa and Cadeddu, is awarded a Research Scholar Grant from the American Cancer Society to support a clinical trial that evaluates stereotactic radiation for small renal masses. Clinical Trial
April 11, 2016 – Dr. Courtney is awarded a $50,000 grant from the Friends of the Comprehensive Cancer Center to support a pilot clinical trial comparing two PET/CT imaging modalities in patients with metastatic RCC receiving standard of care systemic treatment.
March 2016 – Yu and colleagues identify IGFBP5 as a potential tumor suppressor protein downstream of mTORC1 that blocks IGF-1 signaling. Abstract
February 16, 2016 – The Integration Panel for Congressionally-Directed Medical Research Programs for cancer, which Dr. Brugarolas serves on, allocates $50 million to support cancer research and sets the vision for next fiscal year.
January 27, 2016 – A multimodality meeting was held with neurosurgeons, radiation oncologists, and medical oncologists to review UTSW experience in spinal metastases management.
January 14, 2016 – Dr. Mendell reports in Cell the discovery of a noncoding RNA, NORAD, that is required to maintain genomic stability.
January 1, 2016 – John Abrams, Ph.D., reports that p53 mutations may contribute to Wilms tumor development by increasing retrotransposon activity. Abstract
July 8, 2017 – Dr. Hammers discusses "Systemic Therapies for Advanced RCC" at the 48th Japanese Society for Renal Cancer meeting held in Tokyo, Japan.
June 2, 2017 – Drs. Brugarolas and Hammers discuss the best posters on "The Dynamic Landscape of Renal Cell Carcinoma Biomarkers" and "Emerging VEGF-I/O Combinations: Efficacy and Toxicity", respectively, at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago. Summary - Brugarolas • Summary - Hammers
February 17, 2017 – Dr. Brugarolas is asked to identify and review the most important articles in kidney cancer from 2016 from a medical oncologist perspective, and Drs. Margulis and Hammers moderate a session on renal cell cancer at the annual meeting of the American Society of Clinical Oncology for Genitourinary Cancers held in Orlando, FL. Video interviews with Dr. Brugarolas about Adjuvant Therapy for RCC, Role of Immunotherapy, Treatment of non-clear cell RCC, and Immunotherapy Prospects.
January 26, 2017 – Dr. Brugarolas discusses the role of BAP1 in renal cancer at the 8th Weinman Symposium International Conference held in Honolulu, Hawaii.
November 30, 2016 – Dr. Hammers presents an update on Immuno-Oncology at the Immunotherapy Bridge Conference in Naples, Italy.
November 16, 2016 – Dr. Brugarolas speaks about the “Molecular characterization in renal cell carcinoma” at the Genitourinary Oncology Spanish Association Annual Meeting held in Madrid, Spain.
November 10, 2016 – Dr. Brugarolas presents “Best of AUA 2016 in Kidney Cancer” at the meeting of the Spanish Urological Association in San Sebastian, Spain.
November 4, 2016 - Four UT Southwestern investigators, Drs. Brugarolas, Hammers, Hannan, and Margulis give presentations at the 15th International Kidney Cancer Symposium (organized by the Kidney Cancer Association) in Miami, FL.
November 3, 2016 – Dr. Kapur speaks about the HIF-2 inhibitor for treatment of RCC at the 9th European Scientific Oncology Conference in Marbella, Spain.
October 20, 2016 – Dr. Margulis speaks about active surveillance for localized RCC at the 36th Congress of the Société Internationale D’Urologie in Buenos Aires, Argentina.
October 3, 2016 – Dr. Kapur speaks about the molecular genetic classification of RCC, and chairs a session on Cancer Biology Immunology and Therapy at the 2016 NextGen Genomics, Biology, Bioinformatics and Technologies (NGBT) Conference held in Cochin, India.
June 9, 2016 – Drs. Brugarolas, Cadeddu, Courtney, and Lotan, along with several other UT Southwestern faculty, speak at the 2016 annual meeting of the Texas Urological Society held in Dallas.
June 3, 2016 – Dr. Courtney presents results from the Phase I trial of a first-in-class oral HIF-2a inhibitor in patients with advanced ccRCC at the 2016 ASCO meeting held in Chicago.
May 6, 2016 – Dr. Brugarolas discusses personalized medicine for renal cell carcinoma at the American Urological Association's 2016 Annual Meeting in San Diego.
April 7, 2016 – Dr. DeBerardinis gives a keynote presentation on a systems approach to the study of cancer metabolism at the 12th International VHL Medical Symposium in Boston, where Dr. Brugarolas discusses advances in kidney cancer.
March 5, 2016 – Dr. DeBerardinis presents his work on metabolism and tumor growth at the Fondation IPSEN Conference on Tumor Metabolism in San Pedro de Atacama, Chile.
February 22, 2016 – Dr. DeBerardinis gives a talk entitled "Understanding Metabolic Heterogeneity in Cancer Cells and Tumors" at the Keystone Symposium in Banff, Alberta, Canada.
February 12, 2016 – Dr. Brugarolas chairs a session and gives a presentation at the American Association for Cancer Research meeting in New Orleans on modeling cancer in mice.